TG Therapeutics Reports Strong Q1, Significantly Raises 2026 Revenue Guidance, Secures $500M Non-Dilutive Capital, and Expands Buyback to $300M
TGTX sits 39% above its 52-week low of $25.28.
Summary
TG Therapeutics reported strong Q1 2026 results, significantly raised its full-year revenue guidance for BRIUMVI, secured $500 million in non-dilutive capital, and expanded its share repurchase program to $300 million.
Key Events · Earnings and Guidance · TGTX
-
Strong Q1 2026 Financial Performance
Reported Q1 2026 total global revenue of approximately $205 million, with BRIUMVI U.S. net product revenue of $194.8 million, representing approximately 63% quarterly growth over the same period last year. Net income for the quarter was $19.8 million, a significant increase from $5.1 million in Q1 2025.
-
Significantly Raised 2026 Revenue Guidance
Increased full-year 2026 target total global revenue to approximately $925 million and raised full-year 2026 BRIUMVI U.S. net product revenue target to $885-$900 million, up from prior guidance of $825-$850 million.
-
Secured $500 Million Non-Dilutive Capital
Obtained an additional $500 million in non-dilutive capital from Blue Owl Capital, enhancing financial flexibility without diluting existing shareholders.
-
Expanded Share Repurchase Program
Expanded the second share repurchase program from $100 million to $300 million. The company has repurchased $200 million of common stock since the program's inception in 2024, including $100 million during Q1 2026.
Analysis · TGTX · Life Sciences
TG Therapeutics delivered exceptionally strong first-quarter 2026 financial results, significantly exceeding prior year performance with product revenue up 68% and net income up 288%. The company substantially raised its full-year 2026 BRIUMVI U.S. net product revenue guidance from $825-$850 million to $885-$900 million, signaling robust demand and commercial execution for its key drug. Furthermore, the securing of $500 million in non-dilutive capital from Blue Owl Capital significantly strengthens the balance sheet without shareholder dilution. The expansion of the share repurchase program from $100 million to $300 million, with $100 million already executed in Q1, demonstrates strong management confidence and a commitment to returning value to shareholders. These combined factors present a highly positive outlook for the company's financial health and growth trajectory, reinforcing the investment thesis.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 40.2% of the 386 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.51%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TGTX was trading at $35.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $25.28 to $40.99. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.